TOP TEN perturbations for NM_000174 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000174
Selected probe(set): 206883_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000174 (206883_x_at) across 5339 perturbations tested by GENEVESTIGATOR:

ovarian tumor study 16 / normal ovarian surface epithelial cell sample

Relative Expression (log2-ratio):1.2895069
Number of Samples:3 / 5
Experimental ovarian tumor study 16
Human epithelial tumor cell samples from the ovary of patients with papillary serous carcinoma. Samples were derived by laser capture microdissection (LCM).
Control normal ovarian surface epithelial cell sample
Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue.

brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample

Relative Expression (log2-ratio):-1.1881828
Number of Samples:3 / 3
Experimental brefeldin A study 1 (0.5ug/ml; HCT 116)
Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 cell sample
Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

immunoglobulin (IVIG) study 2 (non-responder) / immunoglobulin (IVIG) study 2 (responder)

Relative Expression (log2-ratio):1.1010065
Number of Samples:6 / 4
Experimental immunoglobulin (IVIG) study 2 (non-responder)
Whole blood samples from subjects with Kawasaki disease obtained 36-48 hours after treatment with intravenous immunoglobulins (IVIG; 2g/kg for 1 day). Based on Egami score, patients were predicted to be resistant / non-responsive to the therapy. The Egami scoring system identifies age, days of illness, platelet count, C-reactive protein and alanin aminotransferase to predict resistance to the IVIG treatment and is highly sensitive and specific in Japanese patients. All patients received aspirin (30mg/kg/day) during acute stage of illness. ATC code:---
Control immunoglobulin (IVIG) study 2 (responder)
Whole blood samples from subjects with Kawasaki disease obtained 36-48 hours after treatment with intravenous immunoglobulins (IVIG; 2g/kg for 1 day). Based on Egami score, patients were predicted to have good response to the therapy. The Egami scoring system identifies age, days of illness, platelet count, C-reactive protein and alanin aminotransferase to predict resistance to the IVIG treatment and is highly sensitive and specific in Japanese patients. All patients received aspirin (30mg/kg/day) during acute stage of illness. ATC code:---

polyarticular JIA study 7 (active) / normal PBMC sample

Relative Expression (log2-ratio):1.0963926
Number of Samples:13 / 13
Experimental polyarticular JIA study 7 (active)
Peripheral blood mononuclear cell (PBMC) samples from children with active polyarticular juvenile idiopathic arthritis, rheumatoid factor negative (polyJIA/RFneg.) as defined by the ILAR criteria. All patients were taking oral or subcutaneous methotrexate. Some subjects had in addition etanercept. Active disease stage was defined according to Wallace at al. 2004 as follows: synovitis and/or fever, rash, lymphadenopathy, splenomegaly, uveitis, elevated ESR or CRP or physician global assessment score indicating active disease.
Control normal PBMC sample
Peripheral blood mononuclear cell (PBMC) samples from healthy children (3-15 years old). The children were either undergoing minor orthopedic procedures or were seen for routine health maintenance. Subjects who experienced fever 38?C in the 48 hours prior to the sample collection.

Dengue hemorrhagic fever study 1 (3d) / Dengue fever study 3 (early)

Relative Expression (log2-ratio):1.0637398
Number of Samples:8 / 8
Experimental Dengue hemorrhagic fever study 1 (3d)
Peripheral blood mononuclear cell (PBMC) samples derived from the blood of Venezuelan individuals 3 days after the onset of Dengue hemorrhagic fever.
Control Dengue fever study 3 (early)
Peripheral blood mononuclear cell (PBMC) samples derived from the blood of Venezuelan individuals 3 days after the onset of Dengue fever.

JIA study 2 / normal PBMC sample

Relative Expression (log2-ratio):1.0491238
Number of Samples:13 / 15
Experimental JIA study 2
Peripheral blood mononuclear cell (PBMC) samples from children with juvenile idiopathic arthritis (JIA).
Control normal PBMC sample
Peripheral blood mononuclear cell (PBMC) samples from healthy children (between 7 and 18 years of age) undergoing elective surgery for non-inflammatory conditions.

Turner syndrome study 2 (maternal monosomyX) / normal PBMC sample

Relative Expression (log2-ratio):0.99793816
Number of Samples:16 / 10
Experimental Turner syndrome study 2 (maternal monosomyX)
Peripheral blood mononuclear cells from female patients with Turner syndrome (45, X) and maternal inherited X chromosome.
Control normal PBMC sample
Peripheral blood mononuclear cell (PBMC) sample from healthy female subjects with normal euploid karyotype (46, XX).

septic shock study 2 (0h) / normal blood sample

Relative Expression (log2-ratio):0.9904461
Number of Samples:14 / 25
Experimental septic shock study 2 (0h)
Blood samples from intensive care unit patients shortly after severe septic shock (SAPS II-high). Severity was assessed using SAPS II score. Septic shock was defined as the combination of SIRS and an infection. To be diagnosed with SIRS patients had to show at least two of the following clinical situation: hypothermia (<36?C) or hyperthermia (>38?C), tachycardia (>90/min), tachypnea (>20 breaths/min) and/or arterial PCO2 of 32 mmHg or lower and/or mechanical ventilation, and leukocytosis (>12,000/mm3) or leukopenia (<4,000/mm3). Septic shock was defined as acute circulatory failure (systolic blood pressure <90 mmHg, mean arterial pressure <65 mmHg, or a reduction in systolic blood pressure >40 mmHg from baseline). In order to avoid confounding effects, patients with human immunodeficiency syndrome, hematologic malignancies evolving from insulin-dependent diabetes, dialyzed chronic renal failure, chronic liver disease stages III and more or patients receiving immunosuppressive therapy were excluded from the study. Other clinical characteristics of the group: non-survivor (28.5%), charlson median (1.3-3.8 %), SAPS II on admission median (49-63), duration length in ICU median (6-30), SOFA H6 (9-13), admission (surgery: 57.1%; medical: 42.9%); type of infection (community acquired: 64.29%; hospital acquired: 35.71%), suspected infection (Bacilli Gram (-): 64%; Cocci Gram (+):64%; Fungi: 0%), cell counts (white blood cells: 3.23-15.68 giga/L; lymphocytes: 0.4-1.33; polymorphonuclear cells: 2.5-12.61; monocytes: 0.19-0.66).
Control normal blood sample
Blood samples from healthy volunteers.

asthma study 3 (exacerbation) / asthma study 3 (convalescence)

Relative Expression (log2-ratio):0.9833069
Number of Samples:5 / 5
Experimental asthma study 3 (exacerbation)
Peripheral blood mononuclear cells (PBMCs) derived from atopic subjects during acute asthma exacerbation and post glucocorticoid treatment (inhaled salbutamol and ipratropium bromide at 20 min intervals for first hour, and oral prednisolone 1mg/kg).
Control asthma study 3 (convalescence)
Peripheral blood mononuclear cells (PBMCs) derived from atopic subjects during convalescence (? six weeks after acute asthma exacerbation).

tunicamycin study 2 (2ug/ml; HCT 116) / untreated HCT 116 cell sample

Relative Expression (log2-ratio):-0.93644714
Number of Samples:3 / 3
Experimental tunicamycin study 2 (2ug/ml; HCT 116)
Human colon carcinoma cell line HCT116 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 cell sample
Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.